[西班牙巴斯克地区乳腺癌不同临床分期的治疗费用]
[Cost of breast cancer treatment by clinical stage in the Basque Country, Spain].
作者信息
Arrospide Arantzazu, Soto-Gordoa Myriam, Acaiturri Teresa, López-Vivanco Guillermo, Abecia Luis Carlos, Mar Javier
出版信息
Rev Esp Salud Publica. 2015 Jan-Feb;89(1):93-7. doi: 10.4321/S1135-57272015000100010.
BACKGROUND
The burden of breast cancer is important for the healthcare system. In the context of the evaluation of the breast cancer screening program in the Basque Country it is important to determine the unitary costs related to diagnosis as well as the treatment costs depending on the clinical stage at detection. The main objective was to calculate the total cost and the components of breast cancer (BC) treatment depending on the clinical stage by 2011.
METHODS
The estimated costs include BC diagnosis as so as to initial treatment and follow-up, based on resource consumption and unitary costs of the Basque Health Services. Micro-costing technique was applied based on the clinical guidelines.
RESULTS
Our model showed the estimated loss of productivity due to premature The initial cost was 9.838 for the stage 0, 17.273 for stage I, 22.145 for stage II and 28.776 for stage III. The follow up annual cost was 172 for the stage 0, 908 for stage I, 994 for stage II and 1.166 for stage III. The annual cost for stage IV was 17879.
CONCLUSIONS
Chemotherapy determines the greatest percentage of BC costs. The two main drivers of the total cost of breast cancer are the initial treatment of stages I to III and the cost of stage IV, the latter reaching 50,061 per patient.
背景
乳腺癌负担对医疗保健系统而言至关重要。在评估巴斯克地区的乳腺癌筛查项目时，确定与诊断相关的单位成本以及取决于检测时临床分期的治疗成本非常重要。主要目标是计算截至2011年根据临床分期划分的乳腺癌（BC）治疗总成本及各组成部分。
方法
基于巴斯克卫生服务机构的资源消耗和单位成本，估算成本包括乳腺癌诊断、初始治疗及随访。根据临床指南应用微观成本核算技术。
结果
我们的模型显示了因过早死亡导致的估计生产力损失。0期的初始成本为9838欧元，I期为17273欧元，II期为22145欧元，III期为28776欧元。0期的随访年度成本为172欧元，I期为908欧元，II期为994欧元，III期为1166欧元。IV期的年度成本为17879欧元。
结论
化疗在乳腺癌成本中占比最大。乳腺癌总成本的两个主要驱动因素是I至III期的初始治疗以及IV期的成本，后者每位患者达到50061欧元。
Zotero 插件